CRISPR Biotech Caribou Trims Pipeline and Cuts 32% of Staff to Focus on Two Cancer Cell Therapies

Caribou Biosciences’ restructuring narrows the biotech’s focus to two off-the-shelf cell therapies for blood cancers, whose key data readouts have been pushed out to the second half of 2025. It’s the CRISPR-editing company’s second cash-saving restructuring in the past year. The post CRISPR Biotech Caribou Trims Pipeline and Cuts 32% of Staff to Focus on…

Read More

‘Medicare for All’ Is Back. Now Comes the Hard Part.

As Americans grow increasingly frustrated with their healthcare system, a proposal that has long been kicked around on the Democratic periphery is showing up in debates and on political platforms: “Medicare for All.” According to a 2025 Economist-YouGov poll, nearly 60% of Americans favor a system of Medicare for All, while 85% of Democrats support…

Read More